5 Key Takeaways

• 1

  A post hoc analysis of the TALOS-AMI trial found BMI influences outcomes of antiplatelet therapy in patients with acute myocardial infarction.

• 2

  Patients with BMI < 28 experienced a 46% reduction in adverse events when de-escalating from ticagrelor to clopidogrel.

• 3

  No significant benefit was observed in patients with BMI ≥ 28 when de-escalating antiplatelet therapy.

• 4

  The study involved 2,697 patients who underwent percutaneous coronary intervention for acute myocardial infarction.

• 5

  Findings suggest that de-escalation strategies may have varying outcomes based on BMI, particularly in lower BMI patients.